Dipexium Pharmaceuticals Inc. (NASDAQ:DPRX) was down 7.1% during trading on Monday . The stock traded as low as $11.06 and last traded at $11.71, with a volume of 61,337 shares. The stock had previously closed at $12.60.

Separately, Zacks Investment Research downgraded Dipexium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 9th.

The firm’s market capitalization is $121.76 million. The firm has a 50-day moving average of $10.92 and a 200-day moving average of $9.92.

Dipexium Pharmaceuticals (NASDAQ:DPRX) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.02. On average, equities analysts expect that Dipexium Pharmaceuticals Inc. will post ($2.10) EPS for the current fiscal year.

Dipexium Pharmaceuticals, Inc is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a first-in-class, broad spectrum, topical antibiotic. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.